Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,244 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

40,244 Papers indexed
1,440 Papers AI scored
40,244 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-11-08 10:15 AM
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40244 results
D
Impact of a Multidisciplinary Cancer Predisposition Program on Adherence With Screening Guidelines for Patients With Cancer Predisposition Syndromes.
PMID 42054233 Published: 2026-04-21 Ingested: 2026-08-02 12:06 AM Journal of pediatric hematology/oncology
AI -
Standard 54.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

D
Training European Health Care Providers in Adolescent and Young Adult (AYA) Oncology: The Joint Action Networks of Expertise (JANE) on AYA with Cancer Perspective.
PMID 42050110 Published: 2026-04-28 Ingested: 2026-08-02 12:06 AM Journal of cancer education : the official journal of the American Association for Cancer Education
AI -
Standard 54.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

D
Overview of Endocrine Dysfunction in Children with Turner Syndrome.
PMID 42044425 Published: 2025-11-20 Ingested: 2026-08-02 12:05 AM Turkish archives of pediatrics
AI -
Standard 54.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

D
Primary Cutaneous Cribriform Tumor in a 10-Year-Old Child.
PMID 42042535 Published: 2026-04-15 Ingested: 2026-08-02 12:06 AM Journal of the American Podiatric Medical Association
AI -
Standard 54.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

D
AI -
Standard 54.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

D
When Rare Meets Young: Pediatric Presentation of Desmoplastic Fibroblastoma.
PMID 42036220 Published: 2026-04-26 Ingested: 2026-08-02 12:06 AM Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
AI -
Standard 54.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

D
Ultrasonography of pediatric cutaneous and subcutaneous masses.
PMID 42029919 Published: 2026-04-24 Ingested: 2026-08-02 12:06 AM Pediatric radiology
AI -
Standard 54.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

D
Paratesticular leiomyoma in the pediatric age.
PMID 42028717 Published: 2026-04-15 Ingested: 2026-08-02 12:06 AM Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica
AI -
Standard 54.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

D
Ultrasonography of benign pediatric fibrous and adipocytic lumps.
PMID 42024245 Published: 2026-04-23 Ingested: 2026-08-02 12:06 AM Pediatric radiology
AI -
Standard 54.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

Previous
Page 2710 of 3354
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic